Vall d'Hebron has launched the first human study for a new generation thrombectomy system, developed by Anaconda Biomed, to treat ischemic ictus. It's a prospective multicentric study with 125 patients that aims to evaluate the security and efficacy of the system, especially for rechannelling of cerebral arteries. Assay data will be used for the call in the regulatory for the Food and Drug Administration (FDA) in the US.Ischemic ictus represents between 80 and 85% of all ictus diagnoses. It is produced because of a cerebral arteria obstruction. Resultant ischemia (which means reduction or absence of blood flux) can lead to severe cerebral damage, transitory or irreversible. 30% of the patients suffer a main cerebral blood vessel obstruction. These are the most severe situations, having more sequels and lowest surveillance. This device is specially designed for them.Anaconda's advanced thrombectomy system has a delivery catheter, a unique aspiration funnel-shaped catheter and a stent recover. When unfolded, the funnel expands automatically, adapting to arteries' diameter, up to 5mm. Dr. Marc Ribó, neurologist from the Ictus Unit in Vall d'Hebron and co-funder of Anaconda Biomed explains that: "This device is specifically designed to stop local and temporally the flux in the artery, thus allowing a complete thrombus extraction, without fragmentations. This is the main advantage when compared to actual devices"."This study is being done in different Spanish Hospitals, being coordinated by Vall d'Hebron. It aims to validate previous data that showed statistically increased wellness and revascularization, both in the first and third pass", says Dr. Alejandro Tomassello, Principal Investigator of this study and head of Interventionist Neuroradiology in Vall d'Hebron.This clinical assay is expected to reproduce and confirm the in vitro assays. They have showed a fast and safe endovascular treatment for cerebrovascular ischemic ictus. Dr Francois Salmon, Anaconda's CEO states that: "our mission is to minimize disability and death after an ictus. We expect to use these results to approach this solution to patients"."Vall d'Hebron already included 16 patients to the study, and it is expected an income from nearby hospitals", says Dr. Ribó.Dr. Tomasello states that: "Once finished the patient's inclusion call, we will collect all the data to establish an efficacy and safety profile for Anaconda's thrombectomy system".